The Prostate Cancer Foundation (PCF) & Pfizer Inc. announce

PCF-Pfizer Health Equity Challenge Awards

Request for Proposals (RFP) Release Date:
Feb 10, 2021

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993, PCF has raised over $865 million to support cutting-edge research by 2,300 scientists at over 244 leading cancer centers in 22 countries around the world. Every FDA-approved life-extending treatment for prostate cancer was seeded and supported by PCF. The overall scientific goal of PCF is to cure prostate cancer. Learn more at pcf.org.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. Pfizer's GMG competitive grant program involves a publicly posted RFP that provides detail regarding a specific area of interest, sets timelines for review and approval, and works with a partner organization or an external review panel to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Competitive Grant Program Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope</th>
<th>Global</th>
</tr>
</thead>
</table>

PCF-Pfizer Health Equity Challenge Award Eligibility Criteria

To be eligible:

- Composed of a team of at least three (3) investigators, including one young investigator. Applicant (Principal Investigator; PI) must have a medical or doctoral degree (MD, PhD, ScD or equivalent), an advanced nursing degree (BSN with a MS/PhD), MPH or an advanced degree in Pharmacy, Psychology, Psychiatry, Sociology, Physiotherapy, or Social Work with an expertise in public health disparities relative to prostate cancer

- The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six-years following completion of a professional
degree (see above) or subsequent mentored academic or clinical training program.

- Applicants must be from non-profit/academic research center
- Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria
- Efforts to increase representation of diverse populations within the investigator team(s) and those designing research projects that are participatory and collaborative [inclusion of voices within the communities most impacted by disparities] are encouraged

### Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>• February 10, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>• Oncology – Genitourinary – Prostate Cancer</td>
</tr>
</tbody>
</table>
| Area of Interest / Focus | The intent of this Request for Proposal (RFP) is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management and outcomes of prostate cancer patients in minority and underserved communities. **General Research proposals in the following topic areas are of particular interest:**
  - Identification of barriers in the delivery of equitable healthcare
  - Health Services research programs to study and optimize care delivery |
| Expected Approximate Monetary Range of Grant Applications | • Expected individual grant amounts are in the range of $100K to $150K
• Approximately **$1.5 million** USD are allocated to this general research
• Applications will be reviewed by an expert review panel (ERP)
• The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement |
Key Dates

- **RFP release date**: February 10, 2021
- **Letter of Intent (LOI) due date**: April 9, 2021
  Please note the deadline is 11:59pm Eastern Time (New York, GMT -5).
- **Review of LOIs by ERP**: June 11, 2021
- **Anticipated LOI Notification Date**: June 30, 2021
- **Full Proposal Deadline**: August 30, 2021
  - Only accepted LOIs will be invited to submit full proposals
  Please note the deadline is 11:59pm Eastern Time (New York, GMT -5)
- **Review of Full Proposals by ERP**: November 2021
- **Anticipated Full Proposal Notification Date**: November 19, 2021
- **Anticipated Period of Performance**: December 2021 to December 31, 2023 (projects may be shorter but not longer than two years)

How to Apply

Please go to [www.cybergrants.com/pfizer/loi](http://www.cybergrants.com/pfizer/loi) and sign in.

First-time users should click “Create your password.”

**Requirements for submission:**

Select the following Competitive Grant Program Name:

**2021 Oncology G: PCF-Pfizer Health Equity Challenge Awards**

- Complete all required sections of the online application. See Appendix A for additional details
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page

Questions

If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Dewayne Brumlow (dewayne.brumlow@pfizer.com), with the subject line: “2021 PCF-Pfizer Health Equity Challenge Awards”

- Please click [here](http://www.cybergrants.com/pfizer/loi) to view Frequently Asked Questions regarding the Competitive Grant Program

Grant Agreements

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](http://www.cybergrants.com/pfizer/loi) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
<table>
<thead>
<tr>
<th>Review and Approval Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions.</td>
</tr>
<tr>
<td>The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mechanism by which Applicants will be Notified</th>
</tr>
</thead>
<tbody>
<tr>
<td>All applicants will be notified via email by the dates noted above</td>
</tr>
<tr>
<td>Applicants may be asked for additional clarification during the review period</td>
</tr>
</tbody>
</table>
## Appendix A

### Letter of Intent Requirements

The Letter of Intent (LOI) will be accepted via the online application. When answering the LOI questions in the application please keep the following in mind:

<table>
<thead>
<tr>
<th>Goals and Objectives</th>
<th>• Provide the main goal of the study and the study population. Provide a detailed definition that is directly linked to the primary objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of Need for the Project</td>
<td>• This should reflect your study rationale. Provide a brief description of the medical question and the rationale of how this project addresses the question</td>
</tr>
</tbody>
</table>
| Patient Population/Target Audience | • Describe the primary audience(s) targeted for this project. For Investigator Sponsored Trials, please specify the age and other demographic information for trial population  
• Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the sample size calculation of your study population |
| Project Design and Methods | • Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan |
| Innovation | • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project. |
| Evaluation and Outcomes | • Specify type and frequency of safety, efficacy, and outcome measures. Also indicate the method(s) used to assess measures  
• Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines |
| Anticipated Project Timeline | • Provide an anticipated timeline for your project including project start/end dates |
| Additional Information | • If there is any additional information you feel PCF and Pfizer should be aware of concerning the importance of this project, please summarize here  
• Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant’s career |
| Organization Detail | • This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project |